MIRA Pharmaceuticals' SKNY-1 Shows Promising Oral Bioavailability and Brain Penetration in Preclinical Obesity and Addiction Studies
Key Insights
SKNY-1 (search), an oral CB1 (search)/CB2 (search)/MAO-B (search) modulator, demonstrated favorable oral bioavailability and robust brain penetration supporting once-daily dosing potential in preclinical studies.
Previously published peer-reviewed findings showed approximately 30% body weight reduction, lipid normalization, and attenuated compulsive feeding and nicotine-seeking behaviors in an MC4R-deficient zebrafish model.
The compound's differentiated CNS profile distinguishes it from earlier CB1 (search)-targeting therapies like rimonabant, which were limited by neuropsychiatric adverse effects.
MIRA Pharmaceuticals (search) has announced positive preclinical formulation and pharmacokinetic results for SKNY-1 (search), its oral investigational drug candidate targeting obesity (search) and addiction-related disorders. The new data, combined with recently published peer-reviewed efficacy findings, strengthen the development profile of this first-in-class oral therapeutic designed to modulate multiple pathways involved in metabolic regulation and reward-associated behaviors.
Optimized Formulation and Pharmacokinetic Profile
The preclinical studies evaluated multiple oral formulations to identify an optimized version of SKNY-1 (search) that provides reproducible systemic exposure alongside meaningful distribution into pharmacologically relevant target tissues. Results demonstrated favorable oral bioavailability with peak plasma concentrations observed approximately six to twelve hours after dosing, supporting the potential for convenient once-daily oral administration.
Critically, SKNY-1 (search) achieved robust brain penetration and substantial liver exposure following oral administration, with detectable tissue exposure consistently observed across multiple animals. This dual organ exposure is particularly significant because the central nervous system and liver regulate complementary aspects of appetite, reward signaling, and metabolic homeostasis. Brain penetration may support modulation of neuronal circuits involved in appetite, satiety, and reward-associated behaviors, while liver exposure may contribute to regulation of lipid metabolism, glucose homeostasis, and energy utilization.
"We believe the next generation of obesity (search) therapies should not only help patients lose weight, but also preserve lean body mass, support long-term metabolic health, and provide the convenience of oral administration," said Erez Aminov, CEO of MIRA Pharmaceuticals (search). "These formulation and pharmacokinetic findings further strengthen our confidence in SKNY-1 (search) as a differentiated oral drug candidate designed to address both obesity and addiction through a novel mechanism."
Differentiated CNS Safety Profile
Importantly, robust brain penetration was achieved while maintaining a differentiated central nervous system profile. As previously reported, SKNY-1 (search) was devoid of anxiety-related behavior in a validated preclinical cannabinoid behavioral model despite engaging central cannabinoid pathways. These findings distinguish SKNY-1 from earlier CB1 (search)-targeting therapies, including rimonabant, which were associated with significant neuropsychiatric adverse effects that ultimately limited their clinical utility.
"Earlier CB1 (search)-targeting therapies demonstrated the importance of the pathway, but their development was ultimately limited by neuropsychiatric side effects," said Itzchak Angel, Ph.D., Chief Scientific Advisor at MIRA. "The combination of robust brain penetration together with our previously reported behavioral findings reinforces the differentiated pharmacological profile of SKNY-1 (search) and supports its continued development as a potential next-generation therapy targeting the endocannabinoid system."
SKNY-1 (search) was designed with a differentiated pharmacological profile combining biased CB1 (search) receptor modulation, partial CB2 (search) receptor agonism, and selective MAO-B (search) inhibition without MAO-A inhibition. The Company believes this differentiated pharmacology may allow engagement of central pathways involved in appetite regulation and reward signaling while potentially avoiding the psychiatric limitations that restricted earlier CB1-targeting therapies.
Peer-Reviewed Efficacy Findings
The pharmacokinetic results complement MIRA's recently published peer-reviewed preclinical studies in the International Journal of Molecular Sciences. The publication, titled "SKNY-1 (search), a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity (search)," described in vitro pharmacologic characterization and in vivo findings in an MC4R-deficient zebrafish model.
Key findings from the publication include dose-dependent reduction in body weight following six days of oral administration, with the higher dose group demonstrating approximately 30% reduction relative to baseline. Notably, no significant reduction in whole-body density was observed during the treatment period—a finding relevant to the ongoing clinical focus on lean body mass preservation during weight reduction.
Additional findings included reductions in total cholesterol, low-density lipoprotein (LDL), and hepatic triglyceride accumulation relative to untreated mc4r(G894C) controls, as well as dose-dependent attenuation of high-calorie feeding and nicotine-seeking behaviors in multiple behavioral paradigms. The compound also modulated appetite-regulatory leptin and ghrelin gene expression patterns toward wild-type levels.
"Despite significant advances in obesity (search) treatment, existing therapeutic approaches continue to face limitations related to tolerability, long-term adherence, durability of response, and increasing clinical focus on preservation of lean body mass during weight reduction," said Aminov. "We believe the publication of these peer-reviewed findings further supports the differentiated pharmacological profile of SKNY-1 (search)."
Mechanism of Action
According to the publication, SKNY-1 (search) demonstrated differential engagement of cannabinoid receptor 1 (CB1 (search)) signaling pathways, partial agonist activity at cannabinoid receptor 2 (CB2 (search)), and selective in vitro inhibition of monoamine oxidase B (MAO-B (search)) relative to MAO-A. This multi-target approach is designed to address both the metabolic dysregulation and reward-associated behaviors that contribute to obesity (search) and addiction.
Development Path Forward
MIRA noted that the findings described to date are from short-term preclinical studies in zebrafish models and that additional studies—including mammalian studies, pharmacokinetic evaluations, toxicology studies, and regulatory review—will be required before determining whether SKNY-1 (search) may advance toward clinical development. SKNY-1 has not been approved by the U.S. Food and Drug Administration or any other regulatory authority, and its safety and efficacy have not been established in humans.
The Company plans to continue evaluating the relationship between tissue exposure, pharmacodynamic activity, and therapeutic efficacy as SKNY-1 (search) advances through additional preclinical development.